| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
ICG-DBCO is a fluorescent labeling reagent that does not have a specific pharmacological target. The DBCO group enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This bioorthogonal chemistry allows for specific labeling of azide-modified biomolecules in complex biological environments without the need for toxic copper catalysts.
|
|---|---|
| ln Vitro |
As a fluorescent probe, ICG-DBCO itself does not possess pharmacological activity. Its utility lies in its photophysical properties: near-infrared fluorescence (ex/em ~789/813 nm) provides deep tissue penetration, minimal autofluorescence, and high signal-to-noise ratio. The DBCO functional group enables efficient and specific conjugation to azide-modified targets via SPAAC click chemistry.
|
| ln Vivo |
As a fluorescent probe, ICG-DBCO is used for in vivo imaging applications. When conjugated to azide-modified targeting moieties (e.g., antibodies, peptides, or nanoparticles), the dye enables visualization of specific biomarkers in living organisms. The near-infrared fluorescence allows for non-invasive imaging of deep tissues, making it suitable for preclinical imaging studies and surgical guidance applications.
|
| Enzyme Assay |
Non-cell-based protocols for ICG-DBCO involve click chemistry conjugation and dye characterization. A typical conjugation procedure includes: dissolving ICG-DBCO in anhydrous DMSO, adding to a solution of azide-modified target molecule in appropriate buffer (pH 7.4), incubating at room temperature for 1–24 hours (depending on the reaction rate), and purifying the conjugate by size-exclusion chromatography or dialysis. Labeling efficiency is determined by absorbance at 789 nm.
|
| Cell Assay |
Cellular assays with ICG-DBCO typically involve labeling azide-modified biomolecules on cell surfaces or intracellularly through metabolic labeling. A representative protocol includes: culturing cells with azide-modified sugar or amino acid precursors (e.g., Ac₄ManNAz for glycans, or AHA for proteins), washing, incubating with ICG-DBCO (1–10 μM) for 30–60 minutes at 37°C, washing to remove unbound dye, and imaging using near-infrared fluorescence microscopy or flow cytometry.
|
| Animal Protocol |
In vivo animal imaging studies with ICG-DBCO typically involve administration of the dye-conjugate via intravenous injection. A representative protocol includes: injecting ICG-DBCO-labeled probe (0.1–1 mg/kg) via tail vein into mouse models, allowing circulation and distribution for 1–24 hours, and performing whole-body fluorescence imaging using an in vivo imaging system (IVIS) with appropriate excitation/emission filters (excitation ~780 nm, emission ~810–830 nm). Tissues may be harvested for ex vivo biodistribution analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are determined for the ICG-DBCO conjugate rather than the dye itself. Typical PK parameters for ICG-based probes include rapid clearance from circulation (t₁/₂ of 1–4 hours), distribution to liver and kidneys, and excretion primarily via the hepatobiliary route. The near-infrared fluorescence allows for real-time monitoring of biodistribution in living animals.
|
| Toxicity/Toxicokinetics |
As a fluorescent dye for research use, ICG-DBCO is not intended for human therapeutic use. Standard safety precautions should be followed when handling the dye. The compound should be stored at 4°C, protected from light. Stock solutions in DMSO are stable at 50 mg/mL. ICG-DBCO is also known as a near-infrared fluorescent dye for SPAAC click chemistry.
|
| References | |
| Additional Infomation |
ICG-DBCO (CAS 3024705-52-7) is a powerful tool for bioorthogonal labeling and near-infrared fluorescence imaging. The combination of ICG's excellent photophysical properties (high quantum yield, good photostability) and DBCO's bioorthogonal reactivity enables specific labeling of azide-modified biomolecules in live cells and animals. This reagent is widely used in chemical biology, molecular imaging, and drug delivery research for tracking biomolecules and studying biological processes in real-time.
|
| Molecular Formula |
C63H64N4O5S
|
|---|---|
| Molecular Weight |
989.27
|
| Appearance |
Brown to black solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~50.54 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0108 mL | 5.0542 mL | 10.1085 mL | |
| 5 mM | 0.2022 mL | 1.0108 mL | 2.0217 mL | |
| 10 mM | 0.1011 mL | 0.5054 mL | 1.0108 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
